HWK
0.035
105.9%
MTL
0.001
-50%
JNO
0.045
60.7%
ERD
1.65
-35.5%
AUH
0.003
50%
SRN
0.002
-33.3%
NAE
0.003
50%
BOC
1.7
-26.4%
ZNO
0.048
41.2%
FBR
0.004
-20%
RLC
0.004
33.3%
ROG
0.004
-20%
TEG
0.004
33.3%
VEN
0.004
-20%
ESK
0.69
25.5%
COB
0.205
-19.6%
DMG
0.011
22.2%
HAS
0.655
-19.1%
AUR
0.012
20%
GRL
0.022
-18.5%
CAV
0.006
20%
DTM
0.005
-16.7%
PIL
0.006
20%
ODE
0.015
-16.7%
PWN
0.012
20%
OMG
0.01
-16.7%
CCM
0.057
18.8%
AVH
1.36
-16.6%
NAG
0.019
18.8%
BLG
0.011
-15.4%
PNT
0.013
18.2%
CLA
0.011
-15.4%
ERL
0.007
16.7%
CZN
0.25
-15.3%
NFM
0.021
16.7%
DES
0.195
-15.2%
SKN
0.007
16.7%
HRE
0.057
-14.9%
SLZ
0.014
16.7%
RHT
0.047
-14.5%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

AGN on track for Phase 2 trials during CY24

Argenica Therapeutics (ASX:AGN) has completed the manufacturing of the ARG-007 drug required for Phase 2 clinical trials. The finalised, sterile drug product manufacturing will be completed by the end of the year keeping the Argenica on track for first patient dosing during Q1 CY24 | ASX Announcement: https://announcements.asx.com.au/asxpdf/20231214/pdf/05yjzbqmnd1b00.pdf $AGN #Phase2 #ClinicalTrials #shorts